Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNTX 
BioNTech SE (BNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BNTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $137.62
1 Year Target Price $137.62
| 13 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.93% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 23.86B USD | Price to earnings Ratio - | 1Y Target Price 137.62 |
Price to earnings Ratio - | 1Y Target Price 137.62 | ||
Volume (30-day avg) 21 | Beta 1.4 | 52 Weeks Range 81.20 - 129.27 | Updated Date 09/17/2025 |
52 Weeks Range 81.20 - 129.27 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.98% | Operating Margin (TTM) -167.45% |
Management Effectiveness
Return on Assets (TTM) -2.14% | Return on Equity (TTM) -1.84% |
Valuation
Trailing PE - | Forward PE 7.04 | Enterprise Value 7388028584 | Price to Sales(TTM) 8.29 |
Enterprise Value 7388028584 | Price to Sales(TTM) 8.29 | ||
Enterprise Value to Revenue 2.19 | Enterprise Value to EBITDA 110.81 | Shares Outstanding 240399008 | Shares Floating 93813198 |
Shares Outstanding 240399008 | Shares Floating 93813198 | ||
Percent Insiders 62.69 | Percent Institutions 23.12 |
Upturn AI SWOT
BioNTech SE
Company Overview
History and Background
BioNTech SE was founded in 2008 in Mainz, Germany, by Uu011fur u015eahin and u00d6zlem Tu00fcreci. Initially focused on cancer immunotherapy, it gained prominence through its rapid development of the COVID-19 vaccine with Pfizer, marking a pivotal moment in its history.
Core Business Areas
- Human Therapeutics: Development of mRNA-based therapies for cancer and infectious diseases.
- mRNA Manufacturing: Production of mRNA for clinical trials and commercial use.
- Early Discovery Programs: Research into novel targets and technologies for immunotherapy.
Leadership and Structure
The company is led by CEO Uu011fur u015eahin. The organizational structure includes research, development, and commercial operations, with a focus on mRNA technology.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): An mRNA-based vaccine developed in partnership with Pfizer. Revenue from the vaccine constituted the bulk of the company's revenue in 2021 and 2022. Competitors include Moderna (MRNA), Novavax (NVAX), and other traditional vaccine manufacturers.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with a strong focus on innovation in areas like mRNA therapeutics and personalized medicine.
Positioning
BioNTech SE is a leader in mRNA technology, particularly in vaccine development, holding a strong position in the infectious disease market and expanding into oncology. Its partnership with Pfizer is a significant competitive advantage.
Total Addressable Market (TAM)
The global mRNA therapeutics and vaccines market is expected to reach billions of dollars. BioNTech SE is well positioned to capture a significant share of this TAM, focusing on both infectious diseases and oncology.
Upturn SWOT Analysis
Strengths
- Leading mRNA Technology
- Successful COVID-19 Vaccine
- Strategic Partnership with Pfizer
- Strong Cash Position
- Innovative R&D Pipeline
Weaknesses
- Reliance on COVID-19 Vaccine Revenue
- Limited Commercial Track Record Beyond Vaccine
- Dependence on Pfizer for Distribution
- High R&D Costs
- Regulatory Risks
Opportunities
- Expansion into Oncology
- Development of New mRNA Therapies
- Geographic Expansion
- Strategic Acquisitions
- Partnerships with Other Biopharma Companies
Threats
- Competition from Other Vaccine Manufacturers
- Decreasing COVID-19 Vaccine Demand
- Clinical Trial Failures
- Patent Disputes
- Changes in Regulatory Landscape
Competitors and Market Share
Key Competitors
- MRNA
- LLY
- GILD
- NVAX
Competitive Landscape
BioNTech SE has a strong position in mRNA technology but faces intense competition. MRNA is close rival in COVID-19 vaccine and mRNA therapy. Companies such as LLY and GILD have many more offerings and cover a wider market.
Major Acquisitions
Pharma Lever Name
- Year: 2023
- Acquisition Price (USD millions): 70
- Strategic Rationale: Expand pipeline of innovative therapeutic candidates.
Growth Trajectory and Initiatives
Historical Growth: Rapid growth in 2021 and 2022 driven by vaccine sales, followed by normalization in 2023.
Future Projections: Future growth depends on expanding the pipeline beyond the COVID-19 vaccine and successfully developing mRNA therapies for cancer and other diseases.
Recent Initiatives: Focus on oncology pipeline expansion, collaborations with other biotech firms, and investments in new technologies.
Summary
BioNTech SE leveraged its mRNA technology to become a key player in the COVID-19 vaccine market. While the company's revenue surged in 2021 and 2022, it now faces the challenge of diversifying its pipeline and reducing reliance on COVID-19 vaccine revenue. Its future success hinges on its ability to develop new mRNA therapies, particularly in oncology. The company must also navigate a competitive landscape and address regulatory risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
- Financial Databases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data is approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNTech SE
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-10-10 | Co-Founder, CEO & Chair of the Management Board Dr. Ugur Sahin M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6772 | Website https://www.biontech.de |
Full time employees 6772 | Website https://www.biontech.de | ||
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.